LLY

885.72

+0.88%↑

JNJ

241.97

+0.71%↑

ABBV

212.52

+1.35%↑

NVS

150.45

+1.48%↑

MRK

118.09

-1.33%↓

LLY

885.72

+0.88%↑

JNJ

241.97

+0.71%↑

ABBV

212.52

+1.35%↑

NVS

150.45

+1.48%↑

MRK

118.09

-1.33%↓

LLY

885.72

+0.88%↑

JNJ

241.97

+0.71%↑

ABBV

212.52

+1.35%↑

NVS

150.45

+1.48%↑

MRK

118.09

-1.33%↓

LLY

885.72

+0.88%↑

JNJ

241.97

+0.71%↑

ABBV

212.52

+1.35%↑

NVS

150.45

+1.48%↑

MRK

118.09

-1.33%↓

LLY

885.72

+0.88%↑

JNJ

241.97

+0.71%↑

ABBV

212.52

+1.35%↑

NVS

150.45

+1.48%↑

MRK

118.09

-1.33%↓

Search

Celldex Therapeutics Inc

Abrir

SetorSaúde

30.45 0.53

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.21

Máximo

30.48

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+77.92% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

501M

2.1B

Abertura anterior

29.92

Fecho anterior

30.45

Sentimento de Notícias

By Acuity

100%

0%

322 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mar. de 2026, 17:33 UTC

Notícias Principais

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 de mar. de 2026, 17:00 UTC

Notícias Principais

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 de mar. de 2026, 16:03 UTC

Notícias Principais

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29 de mar. de 2026, 23:47 UTC

Conversa de Mercado
Notícias Principais

Gold Falls Amid Rising Inflation Fears -- Market Talk

29 de mar. de 2026, 23:46 UTC

Conversa de Mercado
Notícias Principais

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29 de mar. de 2026, 23:35 UTC

Conversa de Mercado
Notícias Principais

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29 de mar. de 2026, 23:23 UTC

Conversa de Mercado

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29 de mar. de 2026, 22:34 UTC

Conversa de Mercado

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29 de mar. de 2026, 22:09 UTC

Conversa de Mercado

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29 de mar. de 2026, 21:06 UTC

Conversa de Mercado
Notícias Principais

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29 de mar. de 2026, 21:03 UTC

Conversa de Mercado

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29 de mar. de 2026, 21:01 UTC

Conversa de Mercado
Notícias Principais

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29 de mar. de 2026, 09:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28 de mar. de 2026, 08:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 19:16 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 de mar. de 2026, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 de mar. de 2026, 19:04 UTC

Conversa de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 de mar. de 2026, 19:03 UTC

Conversa de Mercado
Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 19:02 UTC

Conversa de Mercado
Notícias Principais

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 de mar. de 2026, 18:12 UTC

Conversa de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 de mar. de 2026, 17:36 UTC

Notícias Principais

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 de mar. de 2026, 17:34 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 de mar. de 2026, 17:29 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 de mar. de 2026, 16:38 UTC

Conversa de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 de mar. de 2026, 16:32 UTC

Conversa de Mercado
Notícias Principais

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 de mar. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 15:43 UTC

Conversa de Mercado
Notícias Principais

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

77.92% parte superior

Previsão para 12 meses

Média 53.91 USD  77.92%

Máximo 90 USD

Mínimo 24 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

10

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat